test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works

Advanced Search
& Collections
Issue Date   
Sign on to:   
Receive email
My Account
authorized users
Edit Profile   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/5327

Title: 5-Fluorouracil, Epirubicin and Cisplatin in the Treatment of Metastatic Gastric Carcinoma: A Retrospective Analysis of 68 Patients
Authors: Ozkan, Kanat
Turkkan, Evrensel
Ender, Kurt
Mutlu, Demiray
Murat, Arslan
Nalan, Babacan
Abdülmecit, Yildiz
Osman, Manavoglu
Keywords: Metastatic gastric cancer, 5-Fluorouracil, Epirubicin, Cisplatin
Issue Date: 31-Dec-2005
Publisher: Medknow Publications on behalf of Indian Cancer Society
Citation: Indian Journal of Cancer (ISSN: 0019-509X) Vol 42 Num 2
Abstract: BACKGROUND: Gastric cancer is one of the most common types of cancer and one of the most frequent causes of cancer-related death. The majority of gastric cancers show distant metastasis at the time of diagnosis. At present, there is no general agreement over one standard chemotherapy regimen for metastatic gastric cancer. AIMS: We evaluated the activity and toxicity of the combination of 5-Fluorouracil (5-FU), epirubicin and cisplatin (FEP) in previously untreated patients with metastatic gastric cancer. SETTING AND DESIGN: Medical Oncology Department of Uludag University Faculty of Medicine, Bursa; retrospective study. MATERIAL AND METHODS: Sixty-eight patients received 5-FU 300 mg/m2 on Days 1-5, epirubicin 50 mg/m2 on Day 1 and cisplatin 60 mg/m2 on Day 1, every 4 weeks. A median of 3.5 cycles was administered. The response rate, time to disease progression, survival and toxic effects were analyzed. STATISTICAL ANALYSIS USED: Overall survival and time to progression were estimated using Kaplan-Meier method. RESULTS: There were 4 partial responses and 1 complete response (overall response rate 7.3%); 16 patients had stable disease. Median progression-free and overall survival rates were 3.1 months (95% CI 1.9-4) and 6 months (95% CI 4.2-7), respectively. The principal toxicity was myelosupression. Grade 3-4 neutropenia occurred in 27.9%, anemia in 17.6%, and thrombocytopenia in 11.7% of patients. Non-hematological toxicity was mild and manageable. CONCLUSIONS: We concluded that FEP combination as used at the doses and schedules in this study has inferior activity against metastatic gastric cancer.
URI: http://hdl.handle.net/1807/5327
Other Identifiers: http://www.bioline.org.br/abstract?id=cn05016
Rights: Copyright 2005 Indian Journal of Cancer.
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
cn05016.pdf75.04 kBAdobe PDF

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.